GALECTIN THERAPEUTICS INC. Common Stock (par value $0.001 per share) At Market Issuance Sales AgreementAt Market Issuance Sales Agreement • May 19th, 2017 • Galectin Therapeutics Inc • Pharmaceutical preparations • New York
Galectin Therapeutics Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”), with FBR Capital Markets & Co. (“FBR”), as follows:
PSIVIDA CORP. Common Stock (par value $0.001 per share) At Market Issuance Sales AgreementAt Market Issuance Sales Agreement • February 8th, 2017 • pSivida Corp. • Laboratory analytical instruments • New York
pSivida Corp., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”), with FBR Capital Markets & Co. (“FBR”), as follows:
EVOKE PHARMA, INC. Common Stock (par value $0.0001 per share) At Market Issuance Sales AgreementAt Market Issuance Sales Agreement • April 15th, 2016 • Evoke Pharma Inc • Pharmaceutical preparations • New York
Evoke Pharma, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with FBR Capital Markets & Co. (“FBR”), as follows:
NEPHROGENEX, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales AgreementAt Market Issuance Sales Agreement • August 7th, 2015 • NephroGenex, Inc. • Pharmaceutical preparations • New York
NephroGenex, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with MLV & Co. LLC (“MLV”), as follows:
NEPHROGENEX, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales AgreementAt Market Issuance Sales Agreement • August 7th, 2015 • NephroGenex, Inc. • Pharmaceutical preparations • New York
NephroGenex, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with MLV & Co. LLC (“MLV”), as follows:
AVEO PHARMACEUTICALS, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales AgreementAt Market Issuance Sales Agreement • February 27th, 2015 • Aveo Pharmaceuticals Inc • Pharmaceutical preparations • New York
Aveo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”), with MLV & Co. LLC (“MLV”), as follows:
EVOKE PHARMA, INC. Common Stock (par value $0.0001 per share) At Market Issuance Sales AgreementAt Market Issuance Sales Agreement • November 13th, 2014 • Evoke Pharma Inc • Pharmaceutical preparations • New York
Evoke Pharma, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with MLV & Co. LLC (“MLV”), as follows:
SORRENTO THERAPEUTICS, INC. Common Stock (par value $0.0001 per share) At Market Issuance Sales AgreementAt Market Issuance Sales Agreement • November 4th, 2014 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • New York
Sorrento Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”), with MLV & Co. LLC (“MLV”), as follows:
CONATUS PHARMACEUTICALS INC. Common Stock (par value $0.0001 per share) At Market Issuance Sales AgreementAt Market Issuance Sales Agreement • August 14th, 2014 • Conatus Pharmaceuticals Inc. • Pharmaceutical preparations • New York
Conatus Pharmaceuticals Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with MLV & Co. LLC (“MLV”), as follows:
GALECTIN THERAPEUTICS INC. Common Stock (par value $0.001 per share) At Market Issuance Sales AgreementAt Market Issuance Sales Agreement • October 25th, 2013 • Galectin Therapeutics Inc • Pharmaceutical preparations • New York
Galectin Therapeutics Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”), with MLV & Co. LLC (“MLV”), as follows:
CORONADO BIOSCIENCES, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales AgreementAt Market Issuance Sales Agreement • October 5th, 2012 • Coronado Biosciences Inc • Pharmaceutical preparations • New York
Coronado Biosciences, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with MLV & Co. LLC (“MLV”), as follows: